Product Pipeline Pipeline

Our Pipeline

Progenics has a pipeline that includes products in pre-clinical through late-stage development. We are focused on critical unmet diagnostic and therapeutic needs of prostate cancer patients.


PSMA Targeted Oncology

  • 1404
    Tc-99m Diagnostic Imaging Agent

    Prostate Cancer

    1404 is a targeted small molecule imaging agent candidate that visualizes prostate cancer by targeting PSMA.  The expression of PSMA by tumor cells offers the opportunity to “visualize cancer” by imaging 1404’s radioactive payload.  1404 is aimed at improving detection and staging, more precise biopsies, and a targeted treatment plan that utilizes active surveillance as a disease management tool. MORE>

  • PSMA ADC
    Therapeutic

    Prostate Cancer

    PSMA ADC is an Antibody-Drug Conjugate candidate that targets prostate specific membrane antigen, a protein expressed on the surface of almost all prostate cancer tumor cells and in the neovasculature that supplies many other tumors.  This targeted therapeutic is designed to seek out and kill cancer cells with minimal damage to surrounding healthy tissue.  MORE>

  • PyL
    F-18 Diagnostic Imaging Agent

    Prostate Cancer

    PyL™ (also known as [18F]DCFPyL) is a clinical-stage, fluorinated PSMA-targeted PET imaging agent for prostate cancer that was discovered and developed at the Center for Translational Molecular Imaging at the Johns Hopkins University School of Medicine.  A proof-of-concept study published in the April 2015 issue of the Journal of Molecular Imaging and Biology demonstrated that PET imaging with PyL™ showed high levels of PyL™ uptake in sites of putative metastatic disease and primary tumors, suggesting the potential for high sensitivity and specificity in detecting prostate cancer. MORE>

  • 1095
    I-131 Small Molecule Theranostic

    Prostate Cancer

    1095 is a PSMA-targeted small molecule radiopharmaceutical candidate for the treatment of metastatic prostate cancer.  1095 is designed to deliver lethal doses of radiation to prostate cancer cells while causing minimal damage to healthy surrounding tissue.  Memorial Sloan Kettering Cancer Center, a member of the Prostate Cancer Clinical Trials Consortium, has been designated as the principal site for a phase 1 study. MORE>


Oncology

  • Azedra®
    I-131 Theranostic (MIBG)

    SPA Pheochromocytoma / Paraganglioma

    Azedra® is a late-stage ultra-orphan candidate being developed for the treatment of malignant pheochromocytoma and paraganglioma.  Clinical testing is being conducted under a Special Protocol Assessment which may accelerate FDA review and marketing approval decisions. MORE>


Oncology Supportive Care

  • Relistor® SC (AI)

    OIC Advanced Illness

    RELISTOR® subcutaneous injection, a small-molecule mu-opioid receptor antagonist, is approved in the United States for the treatment of opioid induced constipation in patients with advanced illness. Progenics has licensed Relistor® to Salix Pharmaceuticals, Inc., a wholly owned subsidiary of Valeant Pharmaceuticals International, Inc. in markets worldwide.

  • Relistor® SC (CP)

    OIC Chronic Pain

    RELISTOR® subcutaneous injection, a small-molecule mu-opioid receptor antagonist, is approved in the United States for the treatment of opioid induced constipation in adult patients with chronic non-cancer pain. Progenics has licensed Relistor® to Salix Pharmaceuticals, Inc., a wholly owned subsidiary of Valeant Pharmaceuticals International, Inc. in markets worldwide.

  • Relistor® Oral

    OIC Chronic Pain

    A completed phase 3 trial of oral Relistor® has shown a highly significant improvement in RFBM within 4 hours of dosing and in laxation response over 4 weeks.  Salix Pharmaceuticals, Inc., a wholly owned subsidiary of Valeant Pharmaceuticals
    International, Inc. and Progenics are working with regulatory agencies to define a path for marketing approval of this formulation.

  • Relistor® SC (AI-Japan)

    OIC Advanced Illness

Partnered Programs

  • PRO 140

    HIV Viral Entry Inhibitor

    PRO 140 is a humanized anti-CCR5 monoclonal antibody created at Progenics and now developed by CytoDyn Inc.  PRO 140 is in Phase 2 testing as a treatment for human immunodeficiency virus (HIV) infection.  MORE>

  • PRO 391

    Antibodies Targeting C.diff Toxins

    C. difficile is a pair of humanized antibodies that neutralize the disease-causing toxins of Clostridium difficile.  PRO 391 provides a non-antibiotic approach to managing this important and life-threatening disease.  MORE>